Denali Advisors’s Immunovant IMVT Stock Holding History

Denali Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,900	Closed	-$69.2K	–	465
2022 Q4	$69.2K	Buy	+3,900	New	+$49.1K	0.03%	193

Other funds holding IMVT

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Denali Advisors's IMVT Position: Q1 2023 in Review

Denali Advisors sold out of Immunovant (IMVT) in Q1 2023, closing a stake of 3,900 shares — an estimated $69.2K sold.

Denali Advisors first reported a position in IMVT in Q4 2022 and held it in 1 quarter. The position peaked at $69.2K in Q4 2022. 142 funds tracked by Wall St. Rank hold IMVT as of Q1 2023.

Denali Advisors reported no remaining Immunovant position as of Q1 2023 after selling out during the quarter.
Denali Advisors sold 3,900 Immunovant shares in Q1 2023, an estimated $69.2K.
Denali Advisors first reported a position in Immunovant in Q4 2022 and held it in 1 quarter.
Denali Advisors's Immunovant position peaked at $69.2K in Q4 2022.
142 funds tracked by Wall St. Rank held Immunovant as of Q1 2023.

Based on Denali Advisors's 13F filing for Q1 2023, filed 21 Apr 2023.